ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

被引：0
|
作者：
Harrington, Bonnie K. [1 ]
Gulrajani, Michael [2 ]
Covey, Todd [2 ]
Kaptein, Allard [3 ]
Van Lith, Bart [3 ]
Izumi, Raquel [2 ]
Hamdy, Ahmed [2 ]
Ulrich, Roger Glenn [2 ]
Byrd, John C. [4 ]
Lannutti, Brian J. [2 ]
Johnson, Amy J. [4 ]
机构：
[1] Ohio State Univ, Coll Vet Med, Columbus, OH 43210 USA
[2] Acerta Pharma, Redwood City, CA USA
[3] Acerta Pharma, Oss, Netherlands
[4] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
    Jingjing Wu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 9
  • [2] Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
    Wu, Jingjing
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [3] The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile
    Byrd, John C.
    Wierda, William
    Jones, Jeffrey
    O'Brien, Susan
    Brown, Jennifer R.
    Schuh, Anna
    Hillmen, Peter
    Stephens, Deborah M.
    Ghia, Paolo
    Devereux, Steve
    Chaves, Jorge M.
    Barrientos, Jacqueline C.
    Wang, Min Hui
    Huang, Jane
    Covey, Todd
    Navarro, Tasheda
    Rothbaum, Wayne
    Izumi, Raquel
    Hamdy, Ahmed
    Furman, Richard R.
    BLOOD, 2015, 126 (23)
  • [4] The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Harrington, Bonnie K.
    Covey, Todd
    Lannutti, Brian J.
    Izumi, Raquel
    Ulrich, Roger G.
    Byrd, John C.
    Wiestner, Adrian
    Johnson, Amy J.
    Woyach, Jennifer A.
    BLOOD, 2015, 126 (23)
  • [5] ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
    Covey, Todd
    Barf, Tjeerd
    Gulrajani, Michael
    Krantz, Fanny
    van Lith, Bart
    Bibikova, Elena
    van de Kar, Bas
    de Zwart, Edwin
    Hamdy, Ahmed
    Izumi, Raquel
    Kaptein, Allard
    CANCER RESEARCH, 2015, 75
  • [6] Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
    Barf, Tjeerd
    Covey, Todd
    Izumi, Raquel
    van de Kar, Bas
    Gulrajani, Michael
    van Lith, Bart
    van Hoek, Maaike
    de Zwart, Edwin
    Mittag, Diana
    Demont, Dennis
    Verkaik, Saskia
    Krantz, Fanny
    Pearson, Paul G.
    Ulrich, Roger
    Kaptein, Allard
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 363 (02): : 240 - 252
  • [7] ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma
    Gardner, Heather L.
    Harrington, Bonnie K.
    Izumi, Raquel
    Hamdy, Ahmed
    Kaptein, Allard
    Van Lith, Bart
    London, Cheryl A.
    Byrd, John C.
    Johnson, Amy J.
    Kisseberth, William C.
    CANCER RESEARCH, 2014, 74 (19)
  • [8] The novel Bruton's tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model
    Niemann, Carsten U.
    Montraveta, Arnau
    Herman, Sarah E. M.
    Ingallinera, Tim
    Barf, Tjeerd
    Colomer, Dolors
    Wiestner, Adrian
    CANCER RESEARCH, 2014, 74 (19)
  • [9] ACALABRUTINIB, A SECOND-GENERATION BRUTON TYROSINE KINASE (BTK) INHIBITOR, IN PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Wierda, W.
    Jones, J.
    Furman, R.
    Stephens, D.
    Devereux, S.
    Brown, J.
    Hillmen, P.
    Hamdy, A.
    Fardis, M.
    Tawashi, M.
    Wang, M. H.
    Patel, P.
    Mittag, D.
    Krantz, F.
    Rothbaum, W.
    Izumi, R.
    O'Brien, S.
    Byrd, J.
    HAEMATOLOGICA, 2016, 101 : 151 - 151
  • [10] Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).
    Byrd, John C.
    Jones, Jeffrey Alan
    Furman, Richard R.
    Stephens, Deborah Marie
    Devereux, Steve
    Brown, Jennifer R.
    Hillmen, Peter
    Hamdy, Ahmed M.
    Fardis, Maria
    Tawashi, Manal
    Wang, Min Hui
    Patel, Priti
    Mittag, Diana
    Krantz, Fanny
    Rothbaum, Wayne
    Izumi, Raquel
    O'Brien, Susan Mary
    Wierda, William G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345